PTGX - Company ID 0001377121
The table below shows Protagonist Therapeutics, Inc's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$48.94M | $125.36M | -$27.43M | -$34.35M | -$37.67M | -$28.76M |
| Capital expenditure | $215.00K | $545.00K | $242.00K | $10.00K | $273.00K | $140.00K |
| Investing cash flow | $90.89M | -$94.40M | $6.07M | $9.83M | -$4.48M | -$6.79M |
| Dividends paid | - | - | - |
Protagonist Therapeutics, Inc reported operating cash flow of $57.67M for fiscal year 2025. That is down 68.7% from $184.15M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$29.97M (FY 2016) to $57.67M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $23.37M | $11.44M | $7.20M | $26.46M | $16.93M | $979.00K |